secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001193125-24-006599
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin CCO Jeffrey Ajer to step down effective July 1, 2024
-------------------------------------------------------------

- Jeffrey Ajer, EVP and Chief Commercial Officer, will depart on July 1, 2024.
- No successor named; compensation unchanged until departure date.
- Separation treated as without-cause termination; Ajer eligible for severance per employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524006599/0001193125-24-006599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524006599/d719423d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-006599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer